Melinta Therapeutics Publication Highlights Baxdela Activity Against Fluoroquinolone-Non-Susceptible MRSA Pathogens NEW HAVEN, Conn., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing novel antibiotics to treat serious bacterial infections, announced...

Melinta Therapeutics Demonstrates Potential of Pyrrolocytosine Candidate against Gonorrhea New Haven, Conn., June 05, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced that an oral...

Melinta Therapeutics Updates Pyrrolocytosine and Enhanced Macrolide Programs at ECCMID Showcasing Company’s Structure-Based Drug Design New Haven, Conn, April 21, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that...